Effect of Hemodialysis on Total and Free Lenvatinib Concentrations in a Patient With Metastatic Renal Cell Carcinoma
IJU Case Reports · 2025-11 · 8 (6) · 601-603
DOI: 10.1002/iju5.70099 ↗Abstract
ABSTRACT Introduction Lenvatinib (LEN) concentrations in patients undergoing hemodialysis (HD) have not been examined. Herein, we report the effect of HD on total and free LEN concentrations in a patient with mRCC. Case Presentation The hemodialyzed patient was a 55‐year‐old Japanese male who was treated with 20 mg LEN daily. The area under the plasma concentration–time curve for LEN from 0 to 24 h (AUC 0–24 ) was calculated on Day 8 (off HD) and Day 9 (on HD) after starting administration of LEN. For total LEN on Days 8 and 9, the AUC 0–24 was 2553 and 2783 ng × h/mL, respectively. The free LEN concentration just after HD on Day 9 was 40% lower than that at the same time on Day 8 (1.8 vs. 3.0 ng/mL). Conclusion Although the free LEN concentration is reduced just after HD, LEN will have sufficient pharmacological activity on HD days for patients undergoing HD.
EUVIMED